162 related articles for article (PubMed ID: 36180086)
21. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
22. The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer.
Fong KM; Rosenthal A; Giroux DJ; Nishimura KK; Erasmus J; Lievens Y; Marino M; Marom EM; Putora PM; Singh N; Suárez F; Rami-Porta R; Detterbeck F; Eberhardt WEE; Asamura H;
J Thorac Oncol; 2024 May; 19(5):786-802. PubMed ID: 38320664
[TBL] [Abstract][Full Text] [Related]
23. PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors.
Ferrara MG; Martini M; D'Argento E; Forcella C; Vita E; Di Noia V; Sperduti I; Bilotta M; Ribelli M; Damiano P; Cannella A; Stefani A; Pilotto S; Carbone C; Piro G; Milella M; Tortora G; Bria E
Clin Lung Cancer; 2021 Jul; 22(4):351-360. PubMed ID: 33558194
[TBL] [Abstract][Full Text] [Related]
24. Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer.
Gibson AJW; Li H; D'Silva A; Tudor RA; Elegbede AA; Otsuka SM; Bebb DG; Cheung WY
Med Oncol; 2018 Aug; 35(9):117. PubMed ID: 30073425
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancer.
He YY; Zhang XC; Yang JJ; Niu FY; Zeng Z; Yan HH; Xu CR; Guan JL; Zhong WZ; Yang LL; Guo LH; Wu YL
Clin Lung Cancer; 2014 Nov; 15(6):441-7. PubMed ID: 25044104
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors in clinical stage T4N2 locally advanced non-small cell lung cancer.
Arslan D; Tural D; Koca T; Tastekin D; Kaymak Cerkesli A; Basaran H; Gunduz S; Murat Tatli A; Sezgin Goksu S; Uysal M; Kargi A; Kargi B; Koral L; Ibrahim Bassorgun C; Unal D; Mutlu H; Senol Coskun H; Ozdogan M; Bozcuk H
J BUON; 2015; 20(2):573-9. PubMed ID: 26011352
[TBL] [Abstract][Full Text] [Related]
27. Incorporation of EGFR mutation status into M descriptor of new TNM classification influences survival curves in non-small cell lung cancer patients.
Stanic K; Turnsek N; Vrankar M
Radiol Oncol; 2019 Nov; 53(4):453-458. PubMed ID: 31747381
[TBL] [Abstract][Full Text] [Related]
28. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
29. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
[TBL] [Abstract][Full Text] [Related]
30. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
Wu KL; Tsai MJ; Yang CJ; Chang WA; Hung JY; Yen CJ; Shen CH; Kuo TY; Lee JY; Chou SH; Liu TC; Chong IW; Huang MS
Lung Cancer; 2015 May; 88(2):187-94. PubMed ID: 25747806
[TBL] [Abstract][Full Text] [Related]
31. Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California Cancer Registry.
Ou SH; Zell JA
J Thorac Oncol; 2008 Mar; 3(3):216-27. PubMed ID: 18317063
[TBL] [Abstract][Full Text] [Related]
32. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer.
Lee SS; Kim SB; Park SI; Kim YH; Ryu JS; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
Jpn J Clin Oncol; 2007 Nov; 37(11):829-35. PubMed ID: 17951334
[TBL] [Abstract][Full Text] [Related]
33. Surgical Intervention Improves Survival for Metastatic Non-Small Cell Lung Cancer Patients.
Shen H; Cao Y; Li X; Tan Y; Chen J; Yang Z; Kong Y; Yuan Y
Medicine (Baltimore); 2016 May; 95(21):e3800. PubMed ID: 27227958
[TBL] [Abstract][Full Text] [Related]
34. Subdivision of M1 Stage for De Novo Metastatic Breast Cancer to Better Predict Prognosis and Response to Primary Tumor Surgery.
Lin C; Wu J; Ding S; Goh C; Andriani L; Lu S; Shen K; Zhu L
J Natl Compr Canc Netw; 2019 Dec; 17(12):1521-1528. PubMed ID: 31805535
[TBL] [Abstract][Full Text] [Related]
35. Validation of Independent Prognostic Value of Asphericity of
Rogasch JMM; Furth C; Chibolela C; Hofheinz F; Ochsenreither S; Rückert JC; Neudecker J; Böhmer D; von Laffert M; Amthauer H; Frost N
Clin Lung Cancer; 2020 May; 21(3):264-272.e6. PubMed ID: 31839531
[TBL] [Abstract][Full Text] [Related]
36. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
[TBL] [Abstract][Full Text] [Related]
37. [The place of surgery in metastatic non-small cell lung cancer].
Le Pimpec Barthes F; Mordant P; Pricopi C; Foucault C; Dujon A; Riquet M
Rev Mal Respir; 2012 Mar; 29(3):376-83. PubMed ID: 22440301
[TBL] [Abstract][Full Text] [Related]
38. Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer.
Lee P; Bazan JG; Lavori PW; Weerasuriya DK; Quon A; Le QT; Wakelee HA; Graves EE; Loo BW
Clin Lung Cancer; 2012 Jan; 13(1):52-58. PubMed ID: 21703935
[TBL] [Abstract][Full Text] [Related]
39. A laboratory prognostic index model for patients with advanced non-small cell lung cancer.
Ulas A; Turkoz FP; Silay K; Tokluoglu S; Avci N; Oksuzoglu B; Alkis N
PLoS One; 2014; 9(12):e114471. PubMed ID: 25474743
[TBL] [Abstract][Full Text] [Related]
40. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
